Entities / Company
Monte Rosa Therapeutics.
biotechnology company
- Reports this week
- 2
- Active events
- 2
- Connections
- 17
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
Earlier this month
One to three months ago
-
Monte Rosa Therapeutics announced a global license agreement with Novartis and a strategic collaboration with Roche.Well supported6 reports1 development inside
-
Jefferies Financial Group reissued a 'buy' rating on Monte Rosa Therapeutics, whose stock trades on the Nasdaq exchange.Some support3 reports
Gone quiet
No new reports in 90+ days-
Monte Rosa Therapeutics' stock traded on the Nasdaq exchange, and the company disclosed transactions with the SEC, including an insider sale on June 24th.Some support4 reports1 development inside
-
Monte Rosa Therapeutics filed transactions via SEC Form 4 on June 29, involving Chief Medical Officer Filip Janku.Some support1 report
-
Monte Rosa Therapeutics develops molecular glue degrader medicines.Some support1 report1 development inside
-
Monte Rosa Therapeutics published key research insights in the journal Science on July 4, 2025. John Castle served as the Chief Data Officer during this publication.Speculative1 report
No events began in the chosen period. Widen it, or reset.
What's reaching Monte Rosa Therapeutics
Events traced to Monte Rosa Therapeutics, step by step, newest first- Monte Rosa Therapeutics partnership may face changes after Novartis staff moveMonte Rosa Therapeutics may face changes to its partnership with NovartisPossible
- Greater Boston biotech boom may raise opportunities for Monte Rosa TherapeuticsIncreased biotech investment in Greater Boston may boost Monte Rosa Therapeutics' valuation and partnerships.Possible
Around Monte Rosa Therapeutics this week
News at the entities that move Monte Rosa Therapeutics most-
Novartis StructuralSean Maenpaa, with experience at Novartis and Celgene, was appointed SVP Business Development at Clovis Oncology.Moves Monte Rosa Therapeutics
-
Jefferies Financial Group TransactionalGE Vernova received a 'buy' rating and target price raise from Jefferies, alongside required SEC filings on May 27, 2026.Moves Monte Rosa Therapeutics
-
SEC StructuralLaser Photonics Corporation hired Tim Peterman as Chief Financial Officer and engaged CBIZ for financial reporting consulting.Moves Monte Rosa Therapeutics
-
TD Cowen Mentioned togetherTD Cowen upgraded Maze Therapeutics shares to a strong-buy rating, with coverage reported by MarketBeat.Moves Monte Rosa Therapeutics
-
Raymond James Financial OperationalPrimis Financial filed 13F reports with the SEC regarding institutional holdings, accompanied by analyst reports and price targets.Moves Monte Rosa Therapeutics
-
MarketBeat Mentioned togetherBrookfield Wealth Solutions and Paysign are competing for investment capital, while MarketBeat provides analyst recommendations for Paysign.Moves Monte Rosa Therapeutics
Connections
The 10 strongest of 17, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Novartis Structural
Monte Rosa Therapeutics and Novartis maintain a formal, ongoing partnership through global and exclusive licensing agreements for drug development.
-
Filip Janku Structural
Filip Janku serves as the Chief Medical Officer of Monte Rosa Therapeutics.
-
Jefferies Financial Group Transactional
Jefferies Financial Group issued a 'buy' rating on Monte Rosa Therapeutics.
-
SEC Structural
Monte Rosa Therapeutics is subject to mandatory regulatory filing and disclosure requirements enforced by the SEC.
-
Nasdaq Structural
Monte Rosa Therapeutics is a publicly listed company whose trading and existence are governed by the Nasdaq stock exchange.
-
Raymond James Financial Operational
Raymond James Financial provides financial analysis and price targets for Monte Rosa Therapeutics.
-
TD Cowen Mentioned together
TD Cowen provided a stock rating upgrade recommendation for Monte Rosa Therapeutics.
-
MarketBeat Mentioned together
MarketBeat provides analyst ratings and recommendations regarding Monte Rosa Therapeutics.
History
Events by the month they beganOctober 2026
2 eventsSeptember 2026
1 eventAugust 2026
1 eventShow 1 earlier month
June 2026
5 events- Monte Rosa Therapeutics announced a global license agreement with Novartis and a strategic collaboration with Roche.
- Monte Rosa Therapeutics' stock traded on the Nasdaq exchange, and the company disclosed transactions with the SEC, including an insider sale on June 24th.
- Monte Rosa Therapeutics filed transactions via SEC Form 4 on June 29, involving Chief Medical Officer Filip Janku.
- Monte Rosa Therapeutics develops molecular glue degrader medicines.
- Monte Rosa Therapeutics published key research insights in the journal Science on July 4, 2025. John Castle served as the Chief Data Officer during this publication.